CMBA
GDRX icon

C.M. Bidwell & Associates’s GoodRx Holdings GDRX Stock Holding History

C.M. Bidwell & Associates’s Portfolio GDRX Stock Details GDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-70
Closed -$497 – 503
2024
Q1 		$497 Buy
+70
New +$463 ﹤0.01% 444

Other funds holding GDRX

FPM
Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
LCM
Lakewood Capital Management New York $1.58B AUM 0.92% 1-Year Est. Return
SLG
Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PTC
Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

C.M. Bidwell & Associates's GDRX Position: Q2 2024 in Review

C.M. Bidwell & Associates sold out of GoodRx Holdings (GDRX) in Q2 2024, closing a stake of 70 shares — an estimated $497 sold.

C.M. Bidwell & Associates first reported a position in GDRX in Q1 2024 and held it in 1 quarter. The position peaked at $497 in Q1 2024. 165 funds tracked by Wall St. Rank hold GDRX as of Q2 2024.

  • C.M. Bidwell & Associates reported no remaining GoodRx Holdings position as of Q2 2024 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 70 GoodRx Holdings shares in Q2 2024, an estimated $497.
  • C.M. Bidwell & Associates first reported a position in GoodRx Holdings in Q1 2024 and held it in 1 quarter.
  • C.M. Bidwell & Associates's GoodRx Holdings position peaked at $497 in Q1 2024.
  • 165 funds tracked by Wall St. Rank held GoodRx Holdings as of Q2 2024.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2024, filed 13 Aug 2024.